However , the desvenlafaxine group had significantly greater improvement in MADRS scores ( p = .047 ) and in VAS-PI overall pain ( p = .008 ) , back pain ( p = .006 ) , and arm , leg , or joint pain ( p < .001 ) scores than the placebo group .
